 |
Peter Chambré
Chairman of the Board
Peter Chambré is former Chief Executive Officer of Cambridge Antibody Technology Group plc (CAT). He led CAT from 2002 in its transition from technology focused biotechnology company to profitable biopharmaceutical company, until its acquisition by AstraZeneca plc in 2006. Previously he was Chief Operating Officer of Celera Genomics Group and Chief Executive Officer of Bespak plc. He is currently a Non-Executive Director of BTG plc and Spectris plc and advisor to 3i plc, the Private Equity Group.